<?xml version='1.0' encoding='utf-8'?>
<document id="30295407"><sentence text="Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study."><entity charOffset="10-23" id="DDI-PubMed.30295407.s1.e0" text="isavuconazole" /><entity charOffset="27-37" id="DDI-PubMed.30295407.s1.e1" text="tacrolimus" /><entity charOffset="42-51" id="DDI-PubMed.30295407.s1.e2" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30295407.s1.e0" e2="DDI-PubMed.30295407.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s1.e0" e2="DDI-PubMed.30295407.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s1.e0" e2="DDI-PubMed.30295407.s1.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s1.e1" e2="DDI-PubMed.30295407.s1.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s1.e1" e2="DDI-PubMed.30295407.s1.e2" /></sentence><sentence text="Isavuconazole, a triazole antifungal, is an inhibitor of cytochrome P450 3A4, which also metabolizes tacrolimus and sirolimus"><entity charOffset="0-13" id="DDI-PubMed.30295407.s2.e0" text="Isavuconazole" /><entity charOffset="17-25" id="DDI-PubMed.30295407.s2.e1" text="triazole" /><entity charOffset="101-111" id="DDI-PubMed.30295407.s2.e2" text="tacrolimus" /><entity charOffset="116-125" id="DDI-PubMed.30295407.s2.e3" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e0" e2="DDI-PubMed.30295407.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e0" e2="DDI-PubMed.30295407.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e0" e2="DDI-PubMed.30295407.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e0" e2="DDI-PubMed.30295407.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e1" e2="DDI-PubMed.30295407.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e1" e2="DDI-PubMed.30295407.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e1" e2="DDI-PubMed.30295407.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e2" e2="DDI-PubMed.30295407.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s2.e2" e2="DDI-PubMed.30295407.s2.e3" /></sentence><sentence text=" In previous studies, isavuconazole administration increased tacrolimus and sirolimus area under the curve values by 2"><entity charOffset="22-35" id="DDI-PubMed.30295407.s3.e0" text="isavuconazole" /><entity charOffset="61-71" id="DDI-PubMed.30295407.s3.e1" text="tacrolimus" /><entity charOffset="76-85" id="DDI-PubMed.30295407.s3.e2" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30295407.s3.e0" e2="DDI-PubMed.30295407.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s3.e0" e2="DDI-PubMed.30295407.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s3.e0" e2="DDI-PubMed.30295407.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s3.e1" e2="DDI-PubMed.30295407.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s3.e1" e2="DDI-PubMed.30295407.s3.e2" /></sentence><sentence text="3-fold and 1" /><sentence text="8-fold, respectively, in healthy adults and tacrolimus concentration/dose (C/D) ratio by 1"><entity charOffset="44-54" id="DDI-PubMed.30295407.s5.e0" text="tacrolimus" /></sentence><sentence text="3-fold in solid organ transplant patients" /><sentence text=" We aimed to determine the magnitude of effect of isavuconazole administration on tacrolimus and sirolimus C/D ratios in allogeneic hematopoietic stem cell transplant (alloHSCT) patients"><entity charOffset="50-63" id="DDI-PubMed.30295407.s7.e0" text="isavuconazole" /><entity charOffset="82-92" id="DDI-PubMed.30295407.s7.e1" text="tacrolimus" /><entity charOffset="97-108" id="DDI-PubMed.30295407.s7.e2" text="sirolimus C" /><pair ddi="false" e1="DDI-PubMed.30295407.s7.e0" e2="DDI-PubMed.30295407.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s7.e0" e2="DDI-PubMed.30295407.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s7.e0" e2="DDI-PubMed.30295407.s7.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s7.e1" e2="DDI-PubMed.30295407.s7.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s7.e1" e2="DDI-PubMed.30295407.s7.e2" /></sentence><sentence text="" /><sentence text="A retrospective, single-center, single-arm study in adult alloHSCT patients who received at least 10 days of combination therapy with isavuconazole and tacrolimus and/or sirolimus as inpatients or outpatients was conducted"><entity charOffset="134-147" id="DDI-PubMed.30295407.s9.e0" text="isavuconazole" /><entity charOffset="152-162" id="DDI-PubMed.30295407.s9.e1" text="tacrolimus" /><entity charOffset="170-179" id="DDI-PubMed.30295407.s9.e2" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30295407.s9.e0" e2="DDI-PubMed.30295407.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s9.e0" e2="DDI-PubMed.30295407.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s9.e0" e2="DDI-PubMed.30295407.s9.e2" /><pair ddi="false" e1="DDI-PubMed.30295407.s9.e1" e2="DDI-PubMed.30295407.s9.e1" /><pair ddi="false" e1="DDI-PubMed.30295407.s9.e1" e2="DDI-PubMed.30295407.s9.e2" /></sentence><sentence text=" Tacrolimus and sirolimus trough serum concentrations were measured up to twice weekly for up to 4 weeks"><entity charOffset="16-25" id="DDI-PubMed.30295407.s10.e0" text="sirolimus" /></sentence><sentence text="" /><sentence text="Twenty-two patients receiving tacrolimus and twenty patients receiving sirolimus met the inclusion criteria"><entity charOffset="30-40" id="DDI-PubMed.30295407.s12.e0" text="tacrolimus" /><entity charOffset="71-80" id="DDI-PubMed.30295407.s12.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.30295407.s12.e0" e2="DDI-PubMed.30295407.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s12.e0" e2="DDI-PubMed.30295407.s12.e1" /></sentence><sentence text=" The mean C/D ratio increased from baseline by 1" /><sentence text="42-fold for tacrolimus during week 1 (P = 0"><entity charOffset="12-22" id="DDI-PubMed.30295407.s14.e0" text="tacrolimus" /></sentence><sentence text="002) and up to 1" /><sentence text="56-fold for sirolimus during week 2 (P = 0"><entity charOffset="12-21" id="DDI-PubMed.30295407.s16.e0" text="sirolimus" /></sentence><sentence text="02)" /><sentence text=" For the remaining timepoints, tacrolimus and sirolimus C/D ratios were not statistically significantly different from baseline"><entity charOffset="31-41" id="DDI-PubMed.30295407.s18.e0" text="tacrolimus" /><entity charOffset="46-57" id="DDI-PubMed.30295407.s18.e1" text="sirolimus C" /><pair ddi="false" e1="DDI-PubMed.30295407.s18.e0" e2="DDI-PubMed.30295407.s18.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s18.e0" e2="DDI-PubMed.30295407.s18.e1" /></sentence><sentence text="" /><sentence text="In alloHSCT patients, modest increases in tacrolimus and sirolimus C/D ratios from baseline were observed within the first 2 weeks after initiation of isavuconazole"><entity charOffset="42-52" id="DDI-PubMed.30295407.s20.e0" text="tacrolimus" /><entity charOffset="151-164" id="DDI-PubMed.30295407.s20.e1" text="isavuconazole" /><pair ddi="false" e1="DDI-PubMed.30295407.s20.e0" e2="DDI-PubMed.30295407.s20.e0" /><pair ddi="false" e1="DDI-PubMed.30295407.s20.e0" e2="DDI-PubMed.30295407.s20.e1" /></sentence><sentence text="" /></document>